scholarly journals The prognostic value and immune microenvironment association of androgen receptor in HER2 positive early breast invasive ductal carcinoma

2021 ◽  
Author(s):  
Danyang Zhou
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
Invasive Ductal Carcinoma ◽  
Negative Correlation ◽  
Prognostic Value ◽  
Ductal Carcinoma ◽  
Disease Free Survival ◽  
Immune Microenvironment ◽  
Breast Invasive Ductal Carcinoma ◽  
Kaplan Meier

Abstract BackgroundThe prognosis of HER2+ early breast cancer is heterogeneous. AR, as an indicator of prognosis and treatment, is uncertain in HER2+ subtypes. We aimed to investigate the prognostic value of AR and the relationship between AR expression and immune microenvironment in HER2+ early breast invasive ductal carcinoma (IDC).MethodsHER2+ early breast IDC patients diagnosed by pathology who underwent surgery at Sun Yat-sen University Cancer Center from 2016 to 2017 were the main population. All patients included performed AR test and their clinicopathological data were collected. The disease-free survival (DFS) and overall survival (OS) were evaluated by the Kaplan–Meier method and Cox proportional hazards model. AR+ and AR- breast IDCs were matched 1:1 according to age, T stage and N stage for immune infiltration analysis.ResultsA total of 554 patients with HER2+ early breast cancer were included in this retrospective study, regardless of HR status. Taking 10% as the cutoff values of AR, 81.6% of patients were AR positive and 18.4% were AR negative. ER+ (P<0.001) and PR+ (P<0.001) had significant relations with the positive expression of AR. Kaplan-Meier survival curves analysis suggested that AR had close links with OS (P=0.001), not DFS (P=0.051). Eliminating the potential impact caused by HR, AR also predicted a longer OS (P=0.014) and AR was an independent impact factor for OS by multivariate analysis (P=0.036) in HER2+HR- early breast IDC patients. In AR+ and AR- matched HER2+HR- patients, TILs (P=0.043) and PD-L1 (P=0.027) is significantly low in AR+ patients. The strongest negative correlation was observed between AR and PD-L1 (Pearson’s r =-0.299, P=0.001). AR+ seemed to trend a favorable clinical survival in HER2+HR- IDCs with low TILs or positive PD-L1.ConclusionsAR+ were markedly related to the better OS in HER2+HR- early breast cancer, while the negative correlation was observed between AR and PD-L1/TILs. We provided new insights for the prognostic value and immune microenvironment association of AR to optimize treatment strategies in HER2+ early breast IDCs.

Breast Cancer, Chronic Lymphocytic Leukaemia and Mucormycosis

1987 ◽  
Vol 32 (5) ◽  
pp. 150-151 ◽  
Author(s):  
L. G. McAlpine ◽  
D. J. Williams ◽  
J. H. Dagg
Keyword(s):  
Breast Cancer ◽  
Chronic Lymphocytic Leukaemia ◽  
Invasive Ductal Carcinoma ◽  
Lymphocytic Leukaemia ◽  
Ductal Carcinoma ◽  
Breast Tumour ◽  
Tumour Recurrence ◽  
The Other ◽  
Prolonged Survival ◽  
Breast Invasive Ductal Carcinoma

Prolonged survival following diagnosis of lipid-rich carcinoma of breast is unusual1. We report on a patient in whom lipid-rich carcinoma of one breast, invasive ductal carcinoma of the other breast and chronic lymphocytic leukaemia were diagnosed simultaneously; she survived 14 years without breast tumour recurrence and died with atypical mucormycosis.

PD-1 protein and gene expression in early breast cancer: Prognostic implications.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. 545-545
Author(s):  
Ioannis Zerdes ◽  
Alexios Matikas ◽  
John Lövrot ◽  
Emmanouil G. Sifakis ◽  
François Richard ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Expression ◽  
Early Breast Cancer ◽  
Prognostic Value ◽  
Triple Negative ◽  
Meta Analysis ◽  
Disease Free Survival ◽  
Cochrane Library ◽  
Study Cohort ◽  
Mrna Levels

545 Background: We have previously shown the prognostic value of PD-L1 protein and gene expression in early breast cancer (BC), however, the prognostic role of PD-1 expression remains unclear. Methods: The prognostic value of PD-1 in early BC was investigated using three different approaches: i) evaluation of PD-1 at the protein (IHC, immunohistochemistry in tissue microarrays) and mRNA levels in a retrospective patient cohort of 586 patients treated for early BC in Stockholm, Sweden between 1997-2005, ii) systematic review and trial-level meta-analysis of studies published in Medline, Embase, Cochrane Library and Web of Science Core Collection libraries on the prognostic value of PD-1 IHC expression, and iii) pooled analysis of transcriptomic data from 39 publicly available datasets for the prognostic capacity of PD-1 gene expression. Univariate and multivariable Cox regression models were used. Results: In the retrospective study cohort, PD-1 protein was significantly associated with biologically high-risk characteristics. PD-1 protein, but not gene expression, was correlated with improved overall survival (OS) (adjusted HR = 0.73, 95% CI 0.55 – 0.96, p = 0.023 and adjusted HR = 0.88, 95% CI 0.68 – 1.13, p = 0.307, respectively). In the trial-level meta-analysis, 4736 entries were initially identified and 15 studies, including our original cohort, fulfilled the predefined eligibility criteria. PD-1 IHC expression was not prognostic in unselected patients. However, a significant correlation to improved disease-free survival was seen within the triple-negative subtype (pooled multivariate HR = 0.57, 95% CI 0.29 – 0.90, p = 0.02). In the pooled gene expression analysis, PD-1 gene expression was associated with improved OS in the entire population (adjusted HR = 0.89, 95% CI 0.80 – 0.99, p = 0.025) and in basal-like (adjusted HR = 0.77, 95% CI 0.63 – 0.95, p = 0.014) tumors. Conclusions: PD-1 expression at the RNA and protein levels represent promising prognostic factors, especially in the triple-negative and basal-like subtypes. Standardization and further validation are needed prior to clinical implementation.

Prognostic value of p53 in breast invasive ductal carcinoma: an immunohistochemical study on 942 cases

1995 ◽  
Vol 36 (1) ◽  
pp. 71-81 ◽  
Author(s):  
Gaëtan MacGrogan ◽  
Françoise Bonichon ◽  
Isabelle de Mascarel ◽  
Monique Trojani ◽  
Michel Durand ◽  
...  
Keyword(s):  
Invasive Ductal Carcinoma ◽  
Prognostic Value ◽  
Ductal Carcinoma ◽  
Immunohistochemical Study ◽  
Breast Invasive Ductal Carcinoma

scholarly journals Prognostic Significance of plasma albumin to fibrinogen ratio Associated Nomograms in Patients with breast invasive ductal carcinoma

2019 ◽  
Author(s):  
Lihua Zheng ◽  
Feng Liu ◽  
Yaheng Zhao ◽  
Wei Li ◽  
Yan Yang ◽  
...  
Keyword(s):  
Overall Survival ◽  
Invasive Ductal Carcinoma ◽  
Predictive Accuracy ◽  
Ductal Carcinoma ◽  
Prognostic Significance ◽  
Disease Free Survival ◽  
Metastatic Breast ◽  
Survival Outcomes ◽  
Plasma Albumin ◽  
Breast Invasive Ductal Carcinoma

Abstract Background : In the context of breast invasive ductal carcinoma, this research aims to retrospectively evaluate by preoperative plasma albumin to fibrinogen ratio (AFR) and forecast oncological outcome and recurrence. Methods : This reflective study included 230 patients who had surgical procedures at the Fourth Hospital of Hebei Medical University between January 2009 and April 2012 for the treatment of their non-metastatic breast invasive ductal carcinoma. We utilized an optimal value of preoperative plasma fibrinogen and albumin for the patient classification. Additionally, we used the Kaplan-Meier method to extensively evaluate progression-free and cancer-specific survival outcomes. The analysis of the linkages between the albumin to fibrinogen ratio and clinical outcomes was executed through the univariate and multivariate analyses. To construct nomograms and evaluate the survival outcomes, we used a variety of risk factors. We also verified the predictive accuracy through the Harrell's concordance index (C-index). Results : The association of plasma AFR with diminished disease-free survival (DFS) and overall survival (OS) is statistically significant. An independent prognostic indicator is the plasma AFR, as reported by the multivariate analysis, for DFS (HR =1.346; 95% CI:1.107-1.636; p = 0.03) and overall survival (OS) (HR = 1.485; 95% CI: 1.106-1.993; p = 0.008). Two prediction model of OS and DFS based on the AFR was developed. Conclusions : For patients with breast invasive ductal carcinoma, an independent prognostic factor for the outcomes of oncology patients is the elevated preoperative plasma AFR. For DFS and OS, the constructed nomogram demonstrated highly significant predictive accuracy.

scholarly journals EVALUASI TERAPI ADJUVAN DAN KEJADIAN RELAPS PADA PASIEN PREMENOPAUSAL EARLY BREAST CANCER DI RSUP DR. SARDJITO YOGYAKARTA

2017 ◽  
Vol 7 (1) ◽  
pp. 25
Author(s):  
Fef Rukminingsih ◽  
Tri Murti Andayani ◽  
Fita Rahmawati ◽  
Kartika Widayati
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
Ductal Carcinoma ◽  
Disease Free Survival ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Cross Sectional ◽  
Free Survival ◽  
Her 2 ◽  
Disease Free

Terapi adjuvan pada pasien early breast cancer (EBC) bertujuan untuk meningkatkan disease free survival, menurunkan risiko relaps dan menurunkan angka kematian. Tetapi pada kenyataannya masih sering dijumpai, pasien EBC yang telah mendapat terapi adjuvan mengalami relaps. Kejadian relaps sering dihubungkan dengan meningkatnya risiko kematian tanpa memperhatikan jenis pengobatan. Tujuan penelitian ini adalah mengetahui angka kejadian relaps pada pasien premenopausal EBC yang telah mendapatkan terapi adjuvan di RSUP dr. Sardjito Yogyakarta. Penelitian ini merupakan penelitian deskriptif observasional dengan desain cross sectional study menggunakan data retrospektif yang diperoleh dari data rekam medik pasien premenopausal EBC di Poliklinik Kanker Terpadu “Tulip” RSUP dr. Sardjito Yogyakarta yang telah mengalami tindakan pembedahan pada tahun 2010-2013, bersifat hormon responsif dan HER-2 negatif, mendapatkan terapi adjuvan, perempuan dengan umur 18-60 tahun dan  riwayat pemeriksaan sampai bulan Desember 2016. Pasien akan di eksklusi bila mempunyai penyakit penyerta. Dari 30 pasien diketahui sebanyak 46,67% berumur 41-50 tahun, sebanyak 63,33% menunjukkan ekspresi ER-PR positif, sebanyak 93,34% merupakan invasive ductal carcinoma (IDC). Semua pasien mendapatkan terapi adjuvan kemoterapi menggunakan regimen kombinasi dan semua pasien mendapatkan terapi endokrin berupa tamoksifen. Relaps terjadi pada 11 pasien (36,67%) dan kejadian relaps paling banyak adalah metastasis tulang yaitu pada 8 pasien (26,67%).

Early Breast Cancer - Less Axillary Surgery?

Swiss Surgery ◽  
2000 ◽  
Vol 6 (3) ◽  
pp. 116-120 ◽  
Author(s):  
Gambazzi ◽  
Zuber ◽  
Oertli ◽  
Marti ◽  
Kocher ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Sentinel Lymph Node ◽  
Early Breast Cancer ◽  
Axillary Surgery ◽  
Kaplan Meier

Kleine Mammakarzinome werden häufiger entdeckt. Die nodal positiven Fälle werden seltener. Die sentinel lymph node (SLN) Technik könnte die geeignete Methode sein, unnötige Axilladissektionen zu vermeiden. Wir untersuchten ein Kollektiv von Patientinnen mit pT1 Tumoren in Bezug auf Nodalstatus (pT1a,b und c), auf Axillarezidiv sowie auf das Gesamtüberleben. Von 1983 bis 1997 wurden konsekutiv 185 Frauen mit einem Mammakarzinom </= 20mm Durchmesser behandelt. Die Überlebensdaten nach Kaplan-Meier stützten sich auf eine Kohorte aus 117 Patientinnen mit einer medianen Nachsorge von mindestens sieben Jahren. Es fanden sich sieben Patientinnen mit einem pT1a Karzinom, 30 mit einem pT1b Karzinom und 148 mit einem pT1c Karzinom. Im Mittel wurden 16 axilläre Lymphknoten vom Pathologen gezählt. Der axilläre Lymphknotenbefall zeigte eine erwartete Abhängigkeit von der Tumorgrösse: Kein Axillabefall bei nur sieben pT1a, 10% befallene Lymphknoten bei pT1b und 30% bei pT1c Karzinomen. Kein einziges Axillarezidiv wurde während der Beobachtungszeit entdeckt. Das Gesamtüberleben nach zehn Jahren betrug für Patientinnen mit einem pT1a Karzinom 100%, 91% für pT1b und noch 74% für pT1c Karzinome. Die Screening Mammographie entdeckt vermehrt kleinere Mammakarzinome. Die pN+ Stadien nehmen ab. Hier müssen Nutzen und Risiko der Axilladissektion einander kritisch gegenübergestellt werden. Eine selektive Axilladissektion ermöglicht die sentinel lymph node (SLN) Methode, welche in Verbindung mit aufwendigeren histologischen Nachweismethoden den axillären Nodalstatus realistisch wiedergibt.

Expression of Let-7c in invasive ductal carcinoma of breast cancer and its clinical significance

2009 ◽  
Vol 29 (4) ◽  
pp. 400-403
Author(s):  
Shu-rong SHEN ◽  
Jun-yi SHI ◽  
Xian SHEN ◽  
Guan-li HUANG ◽  
Xiang-yang XUE
Keyword(s):  
Breast Cancer ◽  
Clinical Significance ◽  
Invasive Ductal Carcinoma ◽  
Ductal Carcinoma

scholarly journals False-negative frozen section of sentinel nodes in early breast cancer (cT1-2N0) patients

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Zhu-Jun Loh ◽  
Kuo-Ting Lee ◽  
Ya-Ping Chen ◽  
Yao-Lung Kuo ◽  
Wei-Pang Chung ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Early Breast Cancer ◽  
False Negative ◽  
Disease Free Survival ◽  
Axillary Lymph Nodes ◽  
Axillary Lymph ◽  
Frozen Sections ◽  
Sentinel Nodes ◽  
Tumor Emboli

Abstract Background Sentinel lymph node biopsy (SLNB) is the standard approach for the axillary region in early breast cancer patients with clinically negative nodes. The present study investigated patients with false-negative sentinel nodes in intraoperative frozen sections (FNSN) using real-world data. Methods A case–control study with a 1:3 ratio was conducted. FNSN was determined when sentinel nodes (SNs) were negative in frozen sections but positive for metastasis in formalin-fixed paraffin-embedded (FFPE) sections. The control was defined as having no metastasis of SNs in both frozen and FFPE sections. Results A total of 20 FNSN cases and 60 matched controls from 333 SLNB patients were enrolled between April 1, 2005, and November 31, 2009. The demographics and intrinsic subtypes of breast cancer were similar between the FNSN and control groups. The FNSN patients had larger tumor sizes on preoperative mammography (P = 0.033) and more lymphatic tumor emboli on core biopsy (P < 0.001). Four FNSN patients had metastasis in nonrelevant SNs. Another 16 FNSN patients had benign lymphoid hyperplasia of SNs in frozen sections and metastasis in the same SNs from FFPE sections. Micrometastasis was detected in seven of 16 patients, and metastases in nonrelevant SNs were recognized in two patients. All FNSN patients underwent a second operation with axillary lymph node dissection (ALND). After a median follow-up of 143 months, no FNSN patients developed breast cancer recurrence. The disease-free survival, breast cancer-specific survival, and overall survival in FNSN were not inferior to those in controls. Conclusions Patients with a larger tumor size and more lymphatic tumor emboli have a higher incidence of FNSN. However, the outcomes of FNSN patients after completing ALND were noninferior to those without SN metastasis. ALND provides a correct staging for patients with metastasis in nonsentinel axillary lymph nodes.

scholarly journals From Theory to Practice: Bone Health in Women with Early Breast Cancer Treated with Aromatase Inhibitors

2021 ◽  
Vol 28 (2) ◽  
pp. 1067-1076
Author(s):  
Leonor Vasconcelos de Matos ◽  
Leonor Fernandes ◽  
Maria Teresa Neves ◽  
Fátima Alves ◽  
Mafalda Baleiras ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
Aromatase Inhibitors ◽  
Bone Health ◽  
Disease Free Survival ◽  
Prognostic Impact ◽  
Hormone Receptor Positive ◽  
Fracture Cohort ◽  
Fracture Event ◽  
Post Menopausal

Aromatase inhibitors (AI) are extensively used as adjuvant endocrine therapy in post-menopausal women with hormone receptor-positive early breast cancer (HR+ EBC), but their impact on bone health is not negligible. This work aimed to assess bone loss, fracture incidence, and risk factors associated with these events, as well as the prognostic influence of fractures. We have conducted a retrospective cohort study of women with HR+ EBC under adjuvant therapy with AI, during a 3-year period. Four-hundred-and-fifty-one eligible women were reviewed (median age 68 years). Median time under AI was 40 months. A fracture event occurred in 8.4%, mostly in the radium and femoral neck and in older women (mean 74 vs. 68 years, p = 0.006). Age (OR 1.01, 95% CI 1.01–1.07, p = 0.024) and time under AI (OR 1.02, 95% CI 1.00–1.04, p = 0.037) were independent predictors of fracture, with a fair discrimination (AUC 0.71). Analysis of disease-free survival according to fracture event varied between groups, disfavoring the fracture cohort (at 73 months, survival 78.6%, 95% CI, 47.6–92.4 vs. 95.6%, 95% CI, 91.2–97.8, p = 0.027). The multivariate model confirmed the prognostic impact of fracture occurrence (adjusted HR of 3.17, 95% CI 1.10–9.11; p = 0.032). Bone health is often forgotten, despite its great impact in survivorship. Our results validate the pathophysiologic link between EBC and bone metabolism, which translates into EBC recurrence. Further research in this area may help refine these findings. Moreover, early identification of women at higher risk for fractures is warranted.

Sign in / Sign up

Export Citation Format

Share Document